- CSR Summary Not Yet Available
- NCT01453725
- Primary Citation
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGolimumabProduct NameSIMPONI®Therapeutic AreaMuscle, Bone, and Cartilage DiseasesEnrollment198% Female42.9%% White100%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberP07642Data PartnerJohnson & JohnsonCondition StudiedSpondylitis, Ankylosing (Nonradiographic Axial)Mean/Median Age (Years)31.2
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2019-4132 : Predictors of Clinical Response in Non-radiographic Axial Spondyloarthritis; a post hoc analysis of the GO-AHEAD trial
- 2019-4066 : Assessment of treatment outcome with golimumab in nr-axSpA by baseline CRP
- 2019-3893 : Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in patients with ankylosing spondylitis
- 2018-3765 : Predictors of therapeutic and adverse effect outcomes of golimumab